Magnetization Transfer Imaging Provides No Evidence of Demyelination in Methotrexate-Induced Encephalopathy

References

1. 1.↵
   1. Carroll WL,
   2. Bhojwani D,
   3. Min DJ,
   4. et al

   . Pediatric acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2003:102–31
2. 2.↵
   1. Quinn CT,
   2. Kamen BA

   . A biochemical perspective of methotrexate neurotoxicity with insight on nonfolate rescue modalities. J Investig Med 1996;44:522–30

   PubMedWeb of Science
3. 3.↵
   1. Eichler AF,
   2. Batchelor TT,
   3. Henson JW

   . Diffusion and perfusion imaging in subacute neurotoxicity following high-dose intravenous methotrexate. Neuro Oncol 2007;9:373–77

   Abstract/FREE Full Text
4. 4.↵
   1. Sandoval C,
   2. Kutscher M,
   3. Jayabose S,
   4. et al

   . Neurotoxicity of intrathecal methotrexate: MR imaging findings. AJNR Am J Neuroradiol 2003;24:1887–90

   Abstract/FREE Full Text
5. 5.↵
   1. Chu WC,
   2. Chik KW,
   3. Chan YL,
   4. et al

   . White matter and cerebral metabolite changes in children undergoing treatment for acute lymphoblastic leukemia: longitudinal study with MR imaging and 1H MR spectroscopy. Radiology 2003;229:659–69

   CrossRefPubMedWeb of Science
6. 6.↵
   1. Baehring JM,
   2. Fulbright RK

   . Delayed leukoencephalopathy with stroke-like presentation in chemotherapy recipients. J Neurol Neurosurg Psychiatry 2008;79:535–39

   Abstract/FREE Full Text
7. 7.↵
   1. McGowan JC,
   2. Filippi M,
   3. Campi A,
   4. et al

   . Magnetisation transfer imaging: theory and application to multiple sclerosis. J Neurol Neurosurg Psychiatry 1998;64(suppl 1):S66–69

   PubMedWeb of Science
8. 8.↵
   1. Escherich G,
   2. Horstmann MA,
   3. Zimmermann M,
   4. et al

   . Cooperative study group for childhood acute lymphoblastic leukaemia (COALL): long-term results of trials 82,85,89,92 and 97. Leukemia 2010;24:298–308

   CrossRefPubMed
9. 9.↵
   1. Möricke A,
   2. Zimmermann M,
   3. Reiter A,
   4. et al

   . Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia 2010;24:265–84

   CrossRefPubMedWeb of Science
10. 10.↵
    1. Allen JC,
    2. Rosen G

    . Transient cerebral dysfunction following chemotherapy for osteogenic sarcoma. Ann Neurol 1978;3:441–44

    CrossRefPubMedWeb of Science
11. 11.↵
    1. Dufourg MN,
    2. Landman-Parker J,
    3. Auclerc MF,
    4. et al

    . Age and high-dose methotrexate are associated to clinical acute encephalopathy in FRALLE 93 trial for acute lymphoblastic leukemia in children. Leukemia 2007;21:238–47. Epub 2006 Dec 14

    CrossRefPubMedWeb of Science
12. 12.↵
    1. Inaba H,
    2. Khan RB,
    3. Laningham FH,
    4. et al

    . Clinical and radiological characteristics of methotrexate-induced acute encephalopathy in pediatric patients with cancer. Ann Oncol 2008;19:178–84

    Abstract/FREE Full Text
13. 13.↵
    1. Davidson A,
    2. Payne G,
    3. Leach MO,
    4. et al

    . Proton magnetic resonance spectroscopy ((1)H-MRS) of the brain following high-dose methotrexate treatment for childhood cancer. Med Pediatr Oncol 2000;35:28–34

    CrossRefPubMed
14. 14.↵
    1. Giacomini PS,
    2. Levesque IR,
    3. Ribeiro L,
    4. et al

    . Measuring demyelination and remyelination in acute multiple sclerosis lesion voxels. Arch Neurol 2009;66:375–81

    CrossRefPubMedWeb of Science
15. 15.↵
    1. Odrobina EE,
    2. Lam TY,
    3. Pun T,
    4. et al

    . MR properties of excised neural tissue following experimentally induced demyelination. NMR Biomed 2005;18:277–84

    CrossRefPubMed
16. 16.↵
    1. Emmer BJ,
    2. Steens SC,
    3. Steup-Beekman GM,
    4. et al

    . Detection of change in CNS involvement in neuropsychiatric SLE: a magnetization transfer study. J Magn Reson Imaging 2006;24:812–16

    CrossRefPubMedWeb of Science